Health Catalyst Inc (NASDAQ: HCAT) closed the day trading at $8.65 up 4.85% from the previous closing price of $8.25. In other words, the price has increased by $+0.40 from its previous closing price. On the day, 1448361 shares were traded.
Ratios:
For a better understanding of HCAT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.67.
On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $14.
JP Morgan Upgraded its Neutral to Overweight on December 13, 2023, whereas the target price for the stock was revised from $14 to $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 27 when Burton Daniel D. bought 26,200 shares for $7.81 per share. The transaction valued at 204,525 led to the insider holds 1,172,623 shares of the business.
Llewelyn Linda sold 3,262 shares of HCAT for $31,855 on Feb 15. The Chief People Officer now owns 64,786 shares after completing the transaction at $9.77 per share. On Jan 16, another insider, Llewelyn Linda, who serves as the Chief People Officer of the company, sold 3,163 shares for $10.83 each. As a result, the insider received 34,246 and left with 68,048 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 505.40M and an Enterprise Value of 436.74M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.71 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at 1.48 whereas that against EBITDA is -6.40.
Stock Price History:
Over the past 52 weeks, HCAT has reached a high of $14.37, while it has fallen to a 52-week low of $6.60. The 50-Day Moving Average of the stock is 9.55, while the 200-Day Moving Average is calculated to be 10.19.
Shares Statistics:
Over the past 3-months, HCAT traded about 620.53K shares per day on average, while over the past 10 days, HCAT traded about 887.8k shares per day. A total of 58.30M shares are outstanding, with a floating share count of 55.58M. Insiders hold about 5.09% of the company’s shares, while institutions hold 86.80% stake in the company. Shares short for HCAT as of Feb 15, 2024 were 1.43M with a Short Ratio of 2.30, compared to 1.78M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.44% and a Short% of Float of 2.78%.
Earnings Estimates
Current recommendations for the stock of the company come from 12 analysts. On average, analysts expect EPS of $0.03 for the current quarter, with a high estimate of $0.06 and a low estimate of -$0.06, while EPS last year was $0.05. The consensus estimate for the next quarter is $0.08, with high estimates of $0.12 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.45 and -$0.01 for the fiscal current year, implying an average EPS of $0.31. EPS for the following year is $0.51, with 13 analysts recommending between $0.65 and $0.35.
Revenue Estimates
14 analysts predict $75.14M in revenue for the current quarter. It ranges from a high estimate of $79.6M to a low estimate of $74.05M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $71.24M, an estimated increase of 5.50% from the year-ago figure.
A total of 15 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $331M, while the lowest revenue estimate was $306.03M, resulting in an average revenue estimate of $310.03M. In the same quarter a year ago, actual revenue was $295.94M, up 4.80% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $345.57M in the next fiscal year. The high estimate is $353M and the low estimate is $337.8M. The average revenue growth estimate for next year is up 11.50% from the average revenue estimate for this year.
